Minimizing the Inhibitory Effect of Neutralizing Antibody for Efficient Gene Expression in the Liver With Adeno-associated Virus 8 Vectors

This publication has 36 references indexed in Scilit:

• Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
  New England Journal of Medicine, 2011
• Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents
  Clinical and Vaccine Immunology, 2011
• Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia
  Gene Therapy, 2011
• A Barrel of Monkeys: scAAV8 Gene Therapy for Hemophilia in Nonhuman Primates
  Molecular Therapy, 2011
• Long-term Safety and Efficacy Following Systemic Administration of a Self-complementary AAV Vector Encoding Human FIX Pseudotyped With Serotype 5 and 8 Capsid Proteins
  Molecular Therapy, 2011
• Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunity
  Frontiers in Microbiology, 2011
• Preexisting Immunity and Low Expression in Primates Highlight Translational Challenges for Liver-directed AAV8-mediated Gene Therapy
  Molecular Therapy, 2010
• Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors
  Human Gene Therapy, 2010
• Update on Progress and Hurdles in Novel Genetic Therapies for Hemophilia
  Hematology-American Society Hematology Education Program, 2007
• Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates
  Blood, 2006